What is Zacks Research’s Estimate for BMY Q4 Earnings?

Bristol Myers Squibb Company (NYSE:BMY) – Stock analysts at Zacks Research increased their Q4 2026 earnings per share estimates for shares of Bristol Myers Squibb in a report released on Thursday, February 19th. Zacks Research analyst Team now anticipates that the biopharmaceutical company will earn $1.46 per share for the quarter, up from their previous forecast of $1.32. The consensus estimate for Bristol Myers Squibb’s current full-year earnings is $6.74 per share. Zacks Research also issued estimates for Bristol Myers Squibb’s Q2 2027 earnings at $1.55 EPS and Q4 2027 earnings at $1.34 EPS.

BMY has been the subject of a number of other reports. Sanford C. Bernstein reiterated a “market perform” rating on shares of Bristol Myers Squibb in a report on Monday, November 3rd. Scotiabank reissued a “sector perform” rating and issued a $60.00 price objective (up from $53.00) on shares of Bristol Myers Squibb in a research note on Friday, January 9th. UBS Group upgraded Bristol Myers Squibb from a “neutral” rating to a “buy” rating and boosted their target price for the stock from $46.00 to $65.00 in a report on Wednesday, January 7th. Cantor Fitzgerald restated a “neutral” rating on shares of Bristol Myers Squibb in a research note on Monday, November 24th. Finally, Royal Bank Of Canada assumed coverage on shares of Bristol Myers Squibb in a research note on Tuesday. They issued a “sector perform” rating and a $60.00 target price on the stock. Nine equities research analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $60.71.

Bristol Myers Squibb Stock Performance

Shares of BMY opened at $61.61 on Monday. The firm has a market cap of $125.48 billion, a price-to-earnings ratio of 17.86, a price-to-earnings-growth ratio of 0.17 and a beta of 0.29. The company’s fifty day moving average is $56.50 and its 200-day moving average is $50.26. The company has a quick ratio of 1.14, a current ratio of 1.26 and a debt-to-equity ratio of 2.32. Bristol Myers Squibb has a 12 month low of $42.52 and a 12 month high of $63.33.

Bristol Myers Squibb (NYSE:BMY) last announced its quarterly earnings results on Thursday, February 5th. The biopharmaceutical company reported $1.26 EPS for the quarter, missing the consensus estimate of $1.65 by ($0.39). The firm had revenue of $12.50 billion during the quarter, compared to the consensus estimate of $12.24 billion. Bristol Myers Squibb had a net margin of 14.64% and a return on equity of 69.65%. The company’s quarterly revenue was up 1.3% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.67 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS.

Institutional Trading of Bristol Myers Squibb

Hedge funds have recently modified their holdings of the company. Norges Bank bought a new stake in shares of Bristol Myers Squibb during the fourth quarter valued at approximately $1,947,272,000. AQR Capital Management LLC boosted its stake in Bristol Myers Squibb by 172.6% during the fourth quarter. AQR Capital Management LLC now owns 25,796,905 shares of the biopharmaceutical company’s stock worth $1,391,485,000 after buying an additional 16,332,924 shares in the last quarter. Charles Schwab Investment Management Inc. increased its holdings in Bristol Myers Squibb by 16.8% in the 2nd quarter. Charles Schwab Investment Management Inc. now owns 70,802,680 shares of the biopharmaceutical company’s stock valued at $3,277,456,000 after buying an additional 10,195,775 shares during the period. Arrowstreet Capital Limited Partnership raised its stake in shares of Bristol Myers Squibb by 428.5% in the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 11,311,281 shares of the biopharmaceutical company’s stock valued at $523,599,000 after buying an additional 9,171,098 shares in the last quarter. Finally, Bank of New York Mellon Corp lifted its holdings in shares of Bristol Myers Squibb by 47.0% during the 4th quarter. Bank of New York Mellon Corp now owns 24,495,875 shares of the biopharmaceutical company’s stock worth $1,321,308,000 after acquiring an additional 7,837,485 shares during the period. Institutional investors own 76.41% of the company’s stock.

Bristol Myers Squibb Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, February 2nd. Investors of record on Friday, January 2nd were paid a dividend of $0.63 per share. This is a positive change from Bristol Myers Squibb’s previous quarterly dividend of $0.62. This represents a $2.52 annualized dividend and a yield of 4.1%. The ex-dividend date was Friday, January 2nd. Bristol Myers Squibb’s dividend payout ratio is presently 73.04%.

Key Bristol Myers Squibb News

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: FDA accepted the NDA for iberdomide in relapsed/refractory multiple myeloma and granted Priority Review and Breakthrough Therapy designation — a fast regulatory path that could add a new oral therapy to BMY’s oncology franchise and materially boost future revenue if approved. FDA Accepts Bristol Myers Squibb (BMY) NDA for Iberdomide With Priority Review
• Positive Sentiment: Positive top-line registrational Phase 2 results for luspatercept in adults with alpha‑thalassemia — successful data supports a potential label expansion (new indication) and adds to the company’s near-term pipeline value. Bristol Myers Squibb Announces Positive Top-Line Results from Registrational Phase 2 Study of Luspatercept in Adults with Alpha (α)-Thalassemia
• Positive Sentiment: Barclays initiated coverage with an Overweight rating and $75 price target, highlighting pipeline potential and supporting higher analyst sentiment and buy-side interest. Barclays Initiates Bristol Myers (BMY) with Overweight Rating on Pipeline Potential
• Neutral Sentiment: Market commentary and valuation pieces are re‑rating BMY as investors digest the clinical/regulatory wins — these articles analyze upside and valuation multiples but don’t add immediate cash-flow changes. Assessing Bristol Myers Squibb (BMY) Valuation After Key Multiple Myeloma And Alpha Thalassemia Updates
• Neutral Sentiment: BMY will present at the TD Cowen Health Care Conference — an opportunity for management to update investors on pipeline timelines and commercial plans; typically a catalyst for guidance clarity but not an immediate earnings event. Bristol Myers Squibb to Participate in the TD Cowen 46th Annual Health Care Conference
• Negative Sentiment: Analysts and coverage notes continue to flag a looming patent/exclusivity cliff for some key products — a structural risk that could pressure revenue beyond the near-term pipeline gains. Barclays Initiates Bristol Myers (BMY) with Overweight Rating on Pipeline Potential

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.